Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-04
2006-07-04
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S392000, C548S263200, C548S324100
Reexamination Certificate
active
07071223
ABSTRACT:
The present invention provides benzamide inhibitors of the P2X7receptor of the formula:wherein R1–R3are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
REFERENCES:
patent: 4318731 (1982-03-01), Kajioka et al.
patent: 4594099 (1986-06-01), Yamada et al.
patent: 4766233 (1988-08-01), Lyga
patent: 4806145 (1989-02-01), Maravetz
patent: 4906286 (1990-03-01), Lyga
patent: 4906287 (1990-03-01), Lyga et al.
patent: 4909833 (1990-03-01), Kajioka et al.
patent: 5017211 (1991-05-01), Wenger et al.
patent: 5077409 (1991-12-01), Wissner
patent: 5128351 (1992-07-01), Wissner
patent: 5281614 (1994-01-01), Ashton et al.
patent: 5411980 (1995-05-01), Ashton et al.
patent: 5436259 (1995-07-01), Ashton et al.
patent: 5686061 (1997-11-01), Li et al.
patent: 5773646 (1998-06-01), Chandrakumar et al.
patent: 5939418 (1999-08-01), Quan et al.
patent: 5948803 (1999-09-01), Maeda et al.
patent: 5961376 (1999-10-01), Gottschald
patent: 6001862 (1999-12-01), Maeda et al.
patent: 6020357 (2000-02-01), Pinto et al.
patent: 6030990 (2000-02-01), Maeda et al.
patent: 6147101 (2000-11-01), Maeda et al.
patent: 6180844 (2001-01-01), Fujita et al.
patent: 6187797 (2001-02-01), Pruitt et al.
patent: 6201024 (2001-03-01), Baxter et al.
patent: 6201130 (2001-03-01), Schwab et al.
patent: 6218376 (2001-04-01), Kindon et al.
patent: 6242470 (2001-06-01), Baxter et al.
patent: 6258838 (2001-07-01), Baxter et al.
patent: 6265409 (2001-07-01), Cheshire et al.
patent: 6297239 (2001-10-01), deSolms et al.
patent: 6303659 (2001-10-01), Baxter et al.
patent: 6320078 (2001-11-01), Suzuki et al.
patent: 6335333 (2002-01-01), Schwab et al.
patent: 6451824 (2002-09-01), Thorwart et al.
patent: 6492355 (2002-12-01), Alcaraz et al.
patent: 6534492 (2003-03-01), Carlsen et al.
patent: 6555541 (2003-04-01), Furber et al.
patent: 6653312 (2003-11-01), Auvin et al.
patent: 6720452 (2004-04-01), Alcaraz et al.
patent: 6927219 (2005-08-01), Duplantier
patent: 2003/0013704 (2003-01-01), Alcaraz et al.
patent: 2003/0013721 (2003-01-01), Meghani et al.
patent: 2003/0032807 (2003-02-01), Andree et al.
patent: 2003/0040513 (2003-02-01), Baxter et al.
patent: 2003/0186981 (2003-10-01), Duplantier et al.
patent: 2004/0072876 (2004-04-01), Kuroda et al.
patent: 2004/0180894 (2004-09-01), Dombroski et al.
patent: 2005/0009900 (2005-01-01), Dombroski et al.
patent: 0 077 938 (1983-05-01), None
patent: 0 138 527 (1985-04-01), None
patent: 0 514 339 (1992-11-01), None
patent: 0 563 384 (1993-10-01), None
patent: 0 688 773 (1995-12-01), None
patent: WO 86/00072 (1986-01-01), None
patent: WO 92/11242 (1992-07-01), None
patent: WO 93/01177 (1993-01-01), None
patent: WO 93/04686 (1993-03-01), None
patent: WO 95/22532 (1995-08-01), None
patent: WO 96/01254 (1996-01-01), None
patent: WO 98/28269 (1998-07-01), None
patent: WO 99/29686 (1999-06-01), None
patent: WO 00/35864 (2000-06-01), None
patent: WO 00/71509 (2000-11-01), None
patent: WO 01/23378 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 04/058270 (2004-07-01), None
patent: WO 04/058731 (2004-07-01), None
patent: WO 2004058731 (2004-07-01), None
Chang, L., et al., “Potent and Orally Active Angiotension II Receptor Antagonist with Equal Affinity for Human AT1 and AT2 Subtypes,” J. Med. Chem., vol. 38(19), pp. 3741-3758 (Sep. 1995), at p. 3752, lines 18-35, compound 58.
Chang, L., et al., “Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes,” J. Med. Chem., vol. 37(26), pp. 4464-4478 (Dec. 1994), at p. 4468, compound 13, p. 4469, compound 36.
Baxter, A., et al., “Hit-to-Lead Studies: Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists,” Bioorg. Med. Che. Lett., vol. 13(22), pp. 4047-4050 (Nov. 2003), at p. 4048, col. 2, lines 10-14 and Table 1.
Baraldi, P., et al., “Synthesis and Biological Activity of N-Arylpiperazine-Modified Analogues of KN-62, a Potent Antagonist of the Purinergic P2X7 Receptor,” J. Med. Chem., vol. 46(8), pp. 1318-1329 (Apr. 2003), at p. 1320, col. 2,line 30-p. 1321, line 8.
Chang, L., et al., “Triazolinones as Nonpeptide Angiotensin II Antagonists.1.Synthesis and Evaluation as Potent 2,4,5-Trisubstituted Triazolinones,” J. Med. Chem., vol. 36(17), pp. 2558-2568 (Aug. 1993), at p. 2560,lines 14-36;p. 2561,Table I,cmpds 6,10,14.
U.S. Appl. No. 11/168,602, filed Jun. 28, 2005, Chung et al.
U.S. Appl. No. 11/167,828, filed Jun. 27, 2005, Li.
U.S. Appl. No. 11/167,786, filed Jun. 27, 2005, Leonard et al.
Theodoridis et al., “Synthesis and Strucuture-Activity Relationships of 1-Aryl-4-substituted-1,4-dihydro-5H-tetrazol-5-ones, a Novel Class of Pre- and Post-emergence Herbicides”, Pestic. Sci., 1990, vol. 30, pp. 259-274.
Theodoridis et al., “Synthesis and Herbicidal Properties of Aryltriazolinones”, American Chemical Society, 1992, Chapter 14, pp. 134-146.
Lyga et al., “Synthesis, Herbicidal Activity, and Action Mechanism of 2-Aryl-1,2,4-triazine-3,5-diones”, American Chemical Society, 1991, Chapter 14, pp. 170-181.
Dowd et al., “P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint”, British Journal of Pharmacology, vol. 125, No. 2, 1998, pp. 341-346.
Chang et al., “Potent and Orally Active Angiotensin II Receptor Antagonists with Equal Affinity for Human AT1 and AT2 Subtypes”, J. Med. Chem., vol. 38, No. 19, 1995, pp. 3741-3758.
Chang et al., “Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes”, J. Med. Chem., vol. 37, No. 26, 1994, pp. 4464-4478.
Baxter et al., “Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists”, Bioorg. Med. Chem. Lett., vol. 13, No. 22, 2003, pp. 4047-4050.
Baraldi et al., “Synthesis and Biological Activity of N-Arylpiperazine-Modified Analogues of KN-62, a Potent Antagonist of the Purinergic P2X7 Receptor”, J. Med. Chem., vol. 46, No. 8, 2003, pp. 1318-1329.
Chang et al., “Triazolinones as Nonpeptide Angiotensin II Antagonists. 1. Synthesis and Evaluation of Potent 2,4,5-Trisubstituted Triazolinones”, J. Med. Chem., vol. 36, No. 17, 1993, pp. 2558-2568.
Bowers et al., “Pharmacological Analysis of the P2Z-Purinoceptor Present on THP-1 Cells”, Drug Development Research, vol. 37, No. 3, 1996, p. 126.
Dombroski Mark A
Duplantier Allen J.
Subramanyam Chakrapani
Ancona Pamela
Ashbrook Charles W.
Crissy Todd
Pfizer Inc.
Shiao Robert
LandOfFree
Benzamide inhibitors of the P2X 7 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide inhibitors of the P2X 7 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide inhibitors of the P2X 7 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594749